SequelSEC

10x Genomics, Inc. TXG

Laboratory Analytical Instruments · CIK 0001770787 · Fiscal year ends 1231

Revenue
$642.82M
Fiscal year ended 2025-12-31
Operating income
-$60.98M
Fiscal year ended 2025-12-31
Free cash flow
$130.12M
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$1.30BMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float / revenue2.0×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.6×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Laboratory Analytical Instruments filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
CapEx / revenue0.9%0th
Gross margin69.1%100th
FCF margin20.2%89th
SBC / revenue17.0%75th
Operating margin-9.5%60th
Net margin-6.8%59th
Revenue YoY growth5.2%59th
Current ratio4.46x57th

10x Genomics, Inc. (TXG) reported revenue of $642.82M and net income of -$43.54M for the fiscal year ended 2025-12-31. This page shows 9 annual periods of income statement, balance sheet and cash flow figures normalized from 10x Genomics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Laboratory Analytical Instruments.

Income

10x Genomics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Revenue$642.82M$610.78M$618.73M$516.41M$490.49M$298.84M$245.89M$146.31M$71.08M
Cost of revenue$198.94M$196.30M$209.41M$120.39M$74.09M$58.47M$61.03M$28.66M$10.56M
Gross profit$443.88M$414.48M$409.31M$396.02M$416.40M$240.38M$184.86M$117.65M$60.52M
Operating income-$60.98M-$194.56M-$265.33M-$167.94M-$52.25M-$534.14M-$30.57M-$110.76M-$18.38M
Net income-$43.54M-$182.63M-$255.10M-$166.00M-$58.22M-$542.73M-$31.25M-$112.48M-$18.76M
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 124.75Mshares 120.45Mshares 117.17Mshares 113.86Mshares 110.35Mshares 101.15Mshares 39.09MUnavailableUnavailable
Pretax income-$39.91M-$177.70M-$248.76M-$161.97M-$53.72M-$534.48M-$31.03M-$112.40M-$18.74M
Income tax expense$3.64M$4.93M$6.34M$4.03M$4.51M$8.26M$218.00K$87.00K$21.00K
Diluted EPS$-0.35$-1.52$-2.18$-1.46$-0.53$-5.37$-0.80UnavailableUnavailable
Selling, general & administrative$316.13M$344.34M$343.33M$298.30M$257.56M$202.33M$130.83M$87.94M$46.74M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

10x Genomics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Cash & equivalentsUnavailable$344.07M$359.28M$219.75M$587.45M$663.60M$424.17M$65.08M$47.86M
Total assets$1.04B$918.64M$965.14M$1.03B$1.02B$929.34M$605.92M$124.31MUnavailable
Current assets$684.45M$584.39M$596.02M$635.04M$747.59M$774.37M$480.84M$106.24MUnavailable
Total liabilities$245.04M$208.50M$224.10M$223.24M$201.26M$190.27M$185.84M$101.05MUnavailable
Current liabilities$153.45M$117.63M$127.16M$130.96M$110.36M$118.13M$63.05M$32.36MUnavailable
Total equity incl. NCI$796.33M$710.13M$741.04M$805.74M$817.57M$739.07M$420.08M-$219.99M-$112.51M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$243.24MUnavailable
Inventory$56.34M$83.11M$73.71M$81.63M$59.97M$29.96M$15.27M$8.57MUnavailable
Accounts receivable$47.01M$87.86M$114.83M$104.21M$85.25M$51.21M$33.37M$28.09MUnavailable
Goodwill$4.51M$4.51M$4.51M$4.51M$4.51M$0UnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailable$0$19.84M$25.49MUnavailable
Accounts payable$12.73M$12.91M$15.74M$21.60M$17.35M$4.71M$13.03M$8.79MUnavailable

Cash flow

10x Genomics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Operating cash flow$136.05M$6.66M-$15.20M-$33.61M-$21.37M-$217.90M$34.63M-$76.41M-$10.70M
Capital expenditures$5.94M$12.39M$48.60M$131.66M$101.28M$36.67M$42.74M$6.28M$3.76M
Investing cash flow-$13.44M-$32.63M$133.49M-$350.89M-$106.73M-$38.39M-$42.77M-$6.71M-$3.76M
Financing cash flow$6.80M$10.91M$13.67M$15.82M$35.30M$468.91M$414.59M$105.37M$20.58M
Net change in cash$129.90M-$15.22M$131.93M-$368.72M-$92.57M$212.15M$406.40M$22.23M$6.11M
Stock-based compensation$109.12M$140.75M$166.95M$136.85M$95.96M$48.63M$13.33M$2.66M$1.66M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$80.00K
Depreciation & amortization$36.20M$35.88M$35.51M$25.37M$21.12M$14.01M$7.07M$3.90M$4.30M

Derived

10x Genomics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Free cash flow$130.12M-$5.73M-$63.80M-$165.27M-$122.65M-$254.56M-$8.12M-$82.69M-$14.46M
Gross margin69.1%67.9%66.2%76.7%84.9%80.4%75.2%80.4%85.1%
Operating margin-9.5%-31.9%-42.9%-32.5%-10.7%-178.7%-12.4%-75.7%-25.8%
FCF margin20.2%-0.9%-10.3%-32.0%-25.0%-85.2%-3.3%-56.5%-20.3%
SBC / revenue17.0%23.0%27.0%26.5%19.6%16.3%5.4%1.8%2.3%
Current ratio4.46x4.97x4.69x4.85x6.77x6.56x7.63x3.28xUnavailable
Revenue YoY growth5.2%-1.3%19.8%5.3%64.1%21.5%68.1%105.8%Unavailable
Net margin-6.8%-29.9%-41.2%-32.1%-11.9%-181.6%-12.7%-76.9%-26.4%
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenue0.9%2.0%7.9%25.5%20.6%12.3%17.4%4.3%5.3%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open TXG in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-08View SEC filing
10-K · Filed 2026-02-13View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-09View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.